ZIM
AMRI

Zacks Investment Management’s Albany Molecular Research Inc AMRI Stock Holding History

Zacks Investment Management’s Portfolio AMRI Stock Details AMRI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-10,317
Closed -$170K – 798
2016
Q3 		$170K Buy
+10,317
New +$153K ﹤0.01% 616
2014
Q4 		– Sell
-12,977
Closed -$286K – 812
2014
Q3 		$286K Buy
+12,977
New +$266K 0.01% 534

Other funds holding AMRI

PIP
Permian Investment Partners Dallas, Texas $905M AUM 13.43% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
VNIM
Vaughan Nelson Investment Management Houston, Texas $11.3B AUM 53% 1-Year Est. Return
OWP
Obermeyer Wealth Partners Aspen, Colorado $2.17B AUM 19.33% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
ACM
American Capital Management New York $1.86B AUM 20.23% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EWM
Evercore Wealth Management New York $6.36B AUM 20.35% 1-Year Est. Return

Zacks Investment Management's AMRI Position: Q4 2016 in Review

Zacks Investment Management sold out of Albany Molecular Research Inc (AMRI) in Q4 2016, closing a stake of 10,317 shares — an estimated $170K sold.

Zacks Investment Management first reported a position in AMRI in Q3 2014 and held it in 2 quarters. The position peaked at $286K in Q3 2014. 133 funds tracked by Wall St. Rank hold AMRI as of Q4 2016.

  • Zacks Investment Management reported no remaining Albany Molecular Research Inc position as of Q4 2016 after selling out during the quarter.
  • Zacks Investment Management sold 10,317 Albany Molecular Research Inc shares in Q4 2016, an estimated $170K.
  • Zacks Investment Management first reported a position in Albany Molecular Research Inc in Q3 2014 and held it in 2 quarters.
  • Zacks Investment Management's Albany Molecular Research Inc position peaked at $286K in Q3 2014.
  • 133 funds tracked by Wall St. Rank held Albany Molecular Research Inc as of Q4 2016.

Based on Zacks Investment Management's 13F filing for Q4 2016, filed 13 Feb 2017.